Daiichi Sankyo Company has decided to expand its collaborative drug discovery program with universities and research institutions based in Japan, Take a New challenge for Drug diScovery (TaNeDS) Global Program, to Germany, Switzerland and ...
Tags: Daiichi Sankyo, Medicine
Daiichi Sankyo Company is seeking approval for an oral antiplatelet agent prasugrel hydrochloride to treat ischemic heart diseased patients undergoing percutaneous coronary intervention (PCI) in Japan. The company has submitted a new drug ...
Tags: Daiichi Sankyo, Medicine
Daiichi Sankyo Company has launched Pralia subcutaneous injection 60mg syringe (generic name denosumab) for the treatment of osteoporosis, following its manufacturing and marketing approval in Japan. Designed to specifically inhibit an ...
Tags: Daiichi Sankyo, Syringe
Daiichi Sankyo Company has filed a supplemental new drug application for extended indication of anticancer agent Topotecin intravenous drip infusion 40mg, 100mg with the Japan's Ministry of Health, Labor and Welfare. Topotecin intravenous ...
Japan-based Daiichi Sankyo Company has introduced Denotas chewable combination tablets with calcium/natural vitamin D3/magnesium in the country. Calcium, natural vitamin D3, magnesium are present as precipitated calcium ...
Daiichi Sankyo Company and Ranbaxy Laboratories have announced synergistic collaboration in Brazil to expand their respective businessess in the country. As part of the synergy, the companies will launch hybrid business model. Ranbaxy ...
Tags: Daiichi Sankyo Company, Medicine
Daiichi Sankyo Company has opened the Orphan Disease Treatment Institute office inside the Daiichi Sankyo Shinagawa R&D center. Innovation Network Corporation of Japan, a fund managed by Mitsubishi UFJ Capital, and Daiichi Sankyo have ...
Tags: Daiichi Sankyo, Orphan Disease Treatment, Orphan Disease
Daiichi Sankyo Company and Ranbaxy Laboratories have announced plans to combine business operations in Thailand. Both the companies plan to integrate the management of Daiichi Sankyo (Thailand) (DSTH) and Ranbaxy Unichem (RUCL), the ...
Tags: Daiichi Sankyo, Ranbaxy, Hybrid Business
Daiichi Sankyo Mexico, a subsidiary of Daiichi Sankyo Company, has introduced antihypertensive franchise olmesartan medoxomil in Mexico under the name, Openvas. The company has also unveiled Openvas Co, a combination preparation for use ...
Tags: antihypertensive franchise olmesartan medoxomil, pharmaceuticals